Wilmore J H, Ewy G A, Freund B J, Hartzell A A, Jilka S M, Joyner M J, Todd C A, Kinzer S M, Pepin E B
Am J Cardiol. 1985 Apr 26;55(10):142D-148D. doi: 10.1016/0002-9149(85)91071-9.
A study was undertaken to determine if normal healthy subjects can increase their endurance capacity consequent to endurance training during chronic beta-adrenergic blockade. Forty-seven subjects, 17 to 34 years of age, were randomly assigned to 1 of 3 treatments (placebo, propranolol, 160 mg/day, and atenolol, 100 mg/day) and then completed a 15-week aerobic exercise training program. All groups reduced their submaximal steady-state heart rates consequent to training; submaximal oxygen uptake was slightly reduced; submaximal stroke volume was increased only in the placebo and atenolol groups; submaximal cardiac output was generally lower; and arterial-mixed venous oxygen difference was increased after training in all 3 groups, suggesting decreased muscle blood flow and increased oxidative capacity. Maximal oxygen uptake and maximal treadmill time were increased in all 3 groups after training. However, while still on medication the atenolol group had significantly greater increases in maximal oxygen uptake and maximal treadmill time compared with the propranolol group. Because most patients will remain on medication, these results suggest a distinct advantage for cardioselective blocking agents. It is concluded that beta-adrenergic blockade does not reduce the ability of normal healthy subjects to gain the benefits associated with cardiorespiratory endurance training.
一项研究旨在确定正常健康受试者在慢性β-肾上腺素能阻滞剂治疗期间进行耐力训练后,其耐力是否能够提高。47名年龄在17至34岁之间的受试者被随机分配至3种治疗方案之一(安慰剂、普萘洛尔160毫克/天、阿替洛尔100毫克/天),然后完成一项为期15周的有氧运动训练计划。所有组在训练后次最大稳态心率均降低;次最大摄氧量略有降低;仅安慰剂组和阿替洛尔组次最大心输出量增加;次最大心输出量总体较低;所有3组训练后动脉-混合静脉氧分压差均增加,提示肌肉血流量减少、氧化能力增加。所有3组训练后最大摄氧量和最大跑步机运动时间均增加。然而,在仍在服药期间,与普萘洛尔组相比,阿替洛尔组的最大摄氧量和最大跑步机运动时间增加幅度显著更大。由于大多数患者将继续服药,这些结果提示心脏选择性阻滞剂具有明显优势。得出的结论是,β-肾上腺素能阻滞剂不会降低正常健康受试者从心肺耐力训练中获益的能力。